© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Pharma Mar, S.A. (PHMMF) stock remained unchanged at $106.48 a share on OTC. The stock opened at $106.48, fluctuating between $106.48 to $106.48 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 13, 2026 | 106.15 | 106.48 | 106.15 | 106.48 | 10.35K |
| Apr 06, 2026 | 100.60 | 100.60 | 100.60 | 100.60 | 5.5K |
| Mar 31, 2026 | 96.00 | 96.00 | 96.00 | 96.00 | 5.5K |
| Mar 11, 2026 | 92.19 | 92.19 | 92.19 | 92.19 | 3.75K |
| Feb 09, 2026 | 88.72 | 88.72 | 88.72 | 88.72 | 231 |
| Feb 04, 2026 | 90.56 | 90.56 | 90.56 | 90.56 | 175 |
| Jan 09, 2026 | 90.21 | 90.21 | 90.21 | 90.21 | 174 |
| Dec 10, 2025 | 86.26 | 86.26 | 86.26 | 86.26 | 216 |
| Nov 17, 2025 | 84.94 | 86.36 | 84.94 | 86.36 | 1.04K |
| Nov 13, 2025 | 85.34 | 85.34 | 85.34 | 85.34 | 100 |
| Nov 12, 2025 | 86.34 | 86.34 | 86.34 | 86.34 | 100 |
| Oct 14, 2025 | 93.75 | 93.75 | 93.00 | 93.00 | 277 |
| Oct 07, 2025 | 102.75 | 102.75 | 102.75 | 102.75 | 100 |
| Oct 06, 2025 | 104.38 | 104.38 | 104.38 | 104.38 | 100 |
| Oct 03, 2025 | 109.70 | 110.40 | 109.70 | 110.40 | 400 |
| Sep 18, 2025 | 99.90 | 99.90 | 99.90 | 99.90 | 0 |
| Sep 15, 2025 | 99.90 | 99.90 | 99.90 | 99.90 | 300 |
| Sep 11, 2025 | 99.90 | 99.90 | 99.90 | 99.90 | 0 |
| Sep 08, 2025 | 99.90 | 99.90 | 99.90 | 99.90 | 100 |
| Sep 04, 2025 | 96.69 | 96.69 | 96.69 | 96.69 | 0 |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
| Employees | 500 |
| Beta | 0.45 |
| Sales or Revenue | $158.15M |
| 5Y Sales Change% | 0.003% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |